

# Peter Abbink

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8127965/publications.pdf>

Version: 2024-02-01

61  
papers

7,546  
citations

116194

36  
h-index

134545

62  
g-index

63  
all docs

63  
docs citations

63  
times ranked

10234  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. <i>Nature Medicine</i> , 2022, 28, 1288-1296.	15.2	44
2	Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques. <i>Nature Communications</i> , 2021, 12, 1474.	5.8	26
3	A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine. <i>Annals of Internal Medicine</i> , 2021, 174, 585-594.	2.0	44
4	Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice. <i>PLoS Pathogens</i> , 2021, 17, e1009673.	2.1	7
5	Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. <i>Nature Medicine</i> , 2021, 27, 1718-1724.	15.2	39
6	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. <i>Cell</i> , 2020, 183, 185-196.e14.	13.5	25
7	Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics. <i>Nature Biomedical Engineering</i> , 2020, 4, 1030-1043.	11.6	46
8	Origin of rebound virus in chronically SIV-infected Rhesus monkeys following treatment discontinuation. <i>Nature Communications</i> , 2020, 11, 5412.	5.8	9
9	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <i>Science</i> , 2020, 369, 812-817.	6.0	789
10	Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines. <i>Vaccines</i> , 2020, 8, 307.	2.1	18
11	Sustained maternal antibody and cellular immune responses in pregnant women infected with Zika virus and mother to infant transfer of Zika-specific antibodies. <i>American Journal of Reproductive Immunology</i> , 2020, 84, e13288.	1.2	7
12	Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C. <i>Journal of Virology</i> , 2020, 94, .	1.5	5
13	Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. <i>Nature Medicine</i> , 2020, 26, 228-235.	15.2	61
14	Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN- $\beta$ Mice. <i>Cell Host and Microbe</i> , 2019, 26, 591-600.e4.	5.1	26
15	Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers. <i>Pathogens</i> , 2019, 8, 216.	1.2	9
16	Lack of therapeutic efficacy of an antibody to $\beta$ in SIVmac251-infected rhesus macaques. <i>Science</i> , 2019, 365, 1029-1033.	6.0	31
17	Alpha-defensin 5 differentially modulates adenovirus vaccine vectors from different serotypes in vivo. <i>PLoS Pathogens</i> , 2019, 15, e1008180.	2.1	10
18	NS1 DNA vaccination protects against Zika infection through T cell-mediated immunity in immunocompetent mice. <i>Science Advances</i> , 2019, 5, eaax2388.	4.7	64

#	ARTICLE	IF	CITATIONS
19	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. <i>Immunity</i> , 2019, 50, 241-252.e6.	6.6	153
20	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. <i>Journal of Infectious Diseases</i> , 2018, 218, 633-644.	1.9	35
21	Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors. <i>Journal of Virology</i> , 2018, 92, .	1.5	24
22	Therapeutic Efficacy of Vectored PGT121 Gene Delivery in HIV-1-Infected Humanized Mice. <i>Journal of Virology</i> , 2018, 92, .	1.5	24
23	Fetal Neuropathology in Zika Virus-Infected Pregnant Female Rhesus Monkeys. <i>Cell</i> , 2018, 173, 1111-1122.e10.	13.5	104
24	Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors. <i>Journal of Virology</i> , 2018, 92, .	1.5	7
25	Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. <i>Lancet, The</i> , 2018, 391, 563-571.	6.3	165
26	Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy. <i>Nature Communications</i> , 2018, 9, 5429.	5.8	49
27	First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. <i>PLoS ONE</i> , 2018, 13, e0205139.	1.1	32
28	Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy. <i>Journal of Immunology</i> , 2018, 201, 2744-2752.	0.4	11
29	Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. <i>Nature</i> , 2018, 563, 360-364.	13.7	246
30	Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. <i>Nature Communications</i> , 2018, 9, 2441.	5.8	69
31	Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge. <i>PLoS ONE</i> , 2018, 13, e0202820.	1.1	45
32	Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. <i>Nature Medicine</i> , 2018, 24, 721-723.	15.2	46
33	Zika virus vaccines. <i>Nature Reviews Microbiology</i> , 2018, 16, 594-600.	13.6	98
34	Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys. <i>Cell</i> , 2017, 169, 610-620.e14.	13.5	191
35	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. <i>Journal of Virology</i> , 2017, 91, .	1.5	40
36	Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys. <i>Nature Communications</i> , 2017, 8, 15740.	5.8	11

#	ARTICLE	IF	CITATIONS
37	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	106
38	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	87
39	Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. <i>Journal of Virology</i> , 2017, 91, .	1.5	38
40	Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	108
41	Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques. <i>PLoS Pathogens</i> , 2017, 13, e1006487.	2.1	129
42	Rapid development of a DNA vaccine for Zika virus. <i>Science</i> , 2016, 354, 237-240.	6.0	348
43	Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. <i>Science</i> , 2016, 353, 1129-1132.	6.0	461
44	Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. <i>Science</i> , 2016, 353, 1045-1049.	6.0	129
45	Immediate Dysfunction of Vaccine-Elicited CD8+ T Cells Primed in the Absence of CD4+ T Cells. <i>Journal of Immunology</i> , 2016, 197, 1809-1822.	0.4	41
46	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. <i>Nature</i> , 2016, 540, 284-287.	13.7	246
47	Adenovirus serotype 5 vaccine vectors trigger IL-27-dependent inhibitory CD4 <sup>+</sup> T cell responses that impair CD8 <sup>+</sup> T cell function. <i>Science Immunology</i> , 2016, 1, .	5.6	16
48	Vaccine protection against Zika virus from Brazil. <i>Nature</i> , 2016, 536, 474-478.	13.7	460
49	Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences. <i>PLoS Pathogens</i> , 2016, 12, e1005431.	2.1	18
50	Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization. <i>Vaccine Journal</i> , 2015, 22, 1166-1175.	3.2	8
51	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. <i>Science</i> , 2015, 349, 320-324.	6.0	303
52	Induction of HIV-1-Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 HIV-1 Vaccination of Humans. <i>Journal of Infectious Diseases</i> , 2015, 211, 518-528.	1.9	60
53	Construction and Evaluation of Novel Rhesus Monkey Adenovirus Vaccine Vectors. <i>Journal of Virology</i> , 2015, 89, 1512-1522.	1.5	47
54	First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002). <i>Journal of Infectious Diseases</i> , 2014, 210, 1052-1061.	1.9	25

#	ARTICLE	IF	CITATIONS
55	Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys. <i>Cell</i> , 2013, 155, 531-539.	13.5	334
56	Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001). <i>Journal of Infectious Diseases</i> , 2013, 207, 248-256.	1.9	98
57	Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. <i>Nature</i> , 2012, 482, 89-93.	13.7	452
58	Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. <i>Nature</i> , 2009, 457, 87-91.	13.7	433
59	Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys. <i>Journal of Virology</i> , 2008, 82, 4844-4852.	1.5	113
60	Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D. <i>Journal of Virology</i> , 2007, 81, 4654-4663.	1.5	429
61	Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. <i>Nature</i> , 2006, 441, 239-243.	13.7	432